Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Neuroblastoma breakpoint family member 3 (NBPF3) is a human protein-coding gene located at chromosome 1p36.12. It encodes a 633-amino acid protein containing five DUF1220 domains—a hallmark of this family and one of the most rapidly evolving protein domain families in the human lineage. NBPF3's protein sequence is highly repetitive and enriched in acidic residues, resulting in a low isoelectric point. Multiple isoforms exist, with isoform 1 the most common[1][3][4]. The specific function of NBPF3 is still unknown, but the broader NBPF family is hypothesized to be involved in primate brain development, cognitive evolution, and possibly in oncogenic and tumor-suppressor pathways. Variations in NBPF gene dosage and expression have been linked to numerous developmental, neurogenetic, and oncological conditions[4][5]. There are no known drug interactions, known clinical mechanisms of action, or use as approved biomarkers. NBPF3 is not recognized as a classical therapeutic target, as its precise biological activity remains largely speculative based on current evidence[1][3][4][5][6][7][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Neuroblastoma breakpoint family member 3 (NBPF3).